Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00018603 · ClinicalTrials.gov registry record · Phase 1

Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)

A Phase 1 study, sponsored by US Department of Veterans Affairs.

Completed
Registry status
Phase 1
Development phase

NCT00018603: Completed Phase 1 study, sponsored by US Department of Veterans Affairs.

NCT00018603 is a Phase 1 study that has completed, run by US Department of Veterans Affairs. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00018603, a Phase 1 study, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and second, to explore neurobiological mechanisms of action of guanfacine.

Interventions

  • DRUG guanfacine

Trial Details

FieldValue
Start Date 1999-11
Est. Completion 2002-10
Phase Phase 1
US Department of Veterans Affairs

632 total trials

What the finished NCT00018603 record still lists

NCT00018603 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which guanfacine is the first listed.

NCT00018603 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00018603 about?

NCT00018603 is a clinical study titled "Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)". This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and second, to explore neurobiological mechanisms of action of guanfacine.

What is the current status of trial NCT00018603?

This trial is currently completed. It is a Phase 1 study. The study started on 1999-11. Estimated completion is 2002-10.

What interventions are being tested in trial NCT00018603?

The interventions under investigation include: guanfacine (DRUG).

Who is sponsoring clinical trial NCT00018603?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00018603, the US trial registry maintained by the National Library of Medicine. NCT00018603 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.